Key statistics
On Friday, Ocugen Inc (2H51:MUN) closed at 1.15, -39.34% below its 52-week high of 1.89, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.08 |
---|---|
High | 1.15 |
Low | 1.08 |
Bid | 0.8995 |
Offer | 0.9395 |
Previous close | 0.9385 |
Average volume | 12.25k |
---|---|
Shares outstanding | 287.86m |
Free float | 283.79m |
P/E (TTM) | -- |
Market cap | 283.89m USD |
EPS (TTM) | -0.1785 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 11:00 GMT.
More ▼
Announcements
- Ocugen Provides Business Update with Third Quarter 2024 Financial Results
- Ocugen Secures $30 Million in Debt Funding
- Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
- Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
- Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
- Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
- Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
- Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
- Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
More ▼